KR890701108A - 종양요법의 독성효과를 반전시키기 위한 메탈로포르피린의 사용 - Google Patents

종양요법의 독성효과를 반전시키기 위한 메탈로포르피린의 사용

Info

Publication number
KR890701108A
KR890701108A KR1019890700814A KR890700814A KR890701108A KR 890701108 A KR890701108 A KR 890701108A KR 1019890700814 A KR1019890700814 A KR 1019890700814A KR 890700814 A KR890700814 A KR 890700814A KR 890701108 A KR890701108 A KR 890701108A
Authority
KR
South Korea
Prior art keywords
agent
tumor therapy
pharmaceutical composition
toxic effects
snpp
Prior art date
Application number
KR1019890700814A
Other languages
English (en)
Inventor
카파즈 아탈라아
에스 드루몬드 죠오지
에스 위셀 포올
Original Assignee
원본미기재
록커펠러 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 록커펠러 유니버시티 filed Critical 원본미기재
Publication of KR890701108A publication Critical patent/KR890701108A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

종양요법의 독성효과를 반전시키기 위한 메탈로포르피린의 사용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 종양요법을 받고 있는 환자에 대하여 종양요법의 독성효과를 반전(reversal)시킬 필요가 있는 경우, 이러한 반전의 초래에 효과적인 일정량의 SnPP,SnMP 또는 SnI2DP를 투여하는 것에 의한 종양요법의 독성효과 반전방법.
  2. 종양요법을 받고 있는 환자에 대하여 종양요법의 독성효과를 반전시킬 필요가 있는 경우, 이러한 반전의 초래에 효과적인 일정량의 SnPP,SnMP 또는 SnI2DP와 함께, 치료법 상으로 효과적인 양의 화학요법 제제를 공동 투여하는 것에 의한 종양요법의 독성효과 반전방법.
  3. 제 2 항에 있어서, 화학 요법 제제가 안트라사이클린(anthracycline)형항 종양 제제인 종양요법의 독성효과 반전 방법.
  4. 제 3 항에 있어서, 안트라 사이클린형 항 종양 제제가 독소루비신(doxorubicin)인 종양요법의 독성효과 반전방법.
  5. 약제학적으로 허용 가능한 담체와, 주요한 활성 성분으로서의 SnPP,SnMP 또는 SnI2DP와 함께 화학요법 제제로 구성되는 비경구 투여를 위한 약제학적 조성물.
  6. 제 5 항에 있어서, 화학요법 제제가 안트라사이클린형 항 종양 제제인 약제학적 조성물.
  7. 제 6 항에 있어서, 안트라사이클린형 항 종양 제제가 독소루비신인 약제학적 조성물.
  8. 제 5 항, 제 6 항 또는 제 7 항에 있어서, 약제학적 담체와 완충된 등장의 식염수용액인 약제학적 조성물.
  9. 제 5 항, 제 6 항 또는 제 7 항에 있어서, 약제학적 담체와 완충된 등장의 포도당 수용액인 약제학적 조성물.
  10. SnPP,SnMP 또는 SnI2DP와 화학요법 제제로 이루어지는 동결건조된 조성물.
  11. 제10항에 있어서, 화학요법 제제가 안트라사이클린형 항 종양 제제인 동결 건조된 조성물.
  12. 제11항에 있어서, 아트라 사이클린형 항 종양 제제가 독소루비신인 동결 건조된 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890700814A 1987-09-08 1988-09-06 종양요법의 독성효과를 반전시키기 위한 메탈로포르피린의 사용 KR890701108A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9381787A 1987-09-08 1987-09-08
US093.817 1987-09-08
PCT/US1988/003052 WO1989002269A1 (en) 1987-09-08 1988-09-06 Use of metalloporphyrins to reverse the toxic effect of tumor therapy

Publications (1)

Publication Number Publication Date
KR890701108A true KR890701108A (ko) 1989-12-19

Family

ID=22240903

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890700814A KR890701108A (ko) 1987-09-08 1988-09-06 종양요법의 독성효과를 반전시키기 위한 메탈로포르피린의 사용

Country Status (10)

Country Link
EP (1) EP0333831B1 (ko)
JP (1) JPH02501740A (ko)
KR (1) KR890701108A (ko)
AT (1) ATE78164T1 (ko)
AU (1) AU603938B2 (ko)
DE (1) DE3872871T2 (ko)
DK (1) DK225689A (ko)
ES (1) ES2012547A6 (ko)
GR (1) GR1000117B (ko)
WO (1) WO1989002269A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
BR9507643A (pt) * 1994-05-13 1997-09-23 Monsanto Co Métodos de uso para catalisadores de decomposição de peroxinitrito composições farmacéuticas para os mesmos
GB9606293D0 (en) * 1996-03-26 1996-05-29 William Harvey Research Limite Treatment of cancers and other tumours
US7375216B2 (en) 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
US7960371B2 (en) 2006-10-04 2011-06-14 Infacare Pharmaceutical Corporation High-purity large-scale preparation of stannsoporfin
US8735574B2 (en) 2011-03-30 2014-05-27 Infacare Pharmaceutical Corporation Methods for synthesizing metal mesoporphyrins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386087A (en) * 1981-07-01 1983-05-31 Research Foundation Of The City University Of New York N-Substituted metalloporphyrins as anti-tumor agents against PS-P-388(P388) leukemia in animals
DE8506853U1 (de) * 1985-03-08 1985-10-10 Neumeier, Robert, 8183 Rottach-Egern Verschlußkopf eines aufblasbaren Luftballons
US4668670A (en) * 1986-06-20 1987-05-26 The Rockefeller University Tin diiododeuteroporphyrin and therapeutic use thereof
US4692439A (en) * 1986-06-20 1987-09-08 The Rockefeller University Therapeutic use of tin diiododeuteroporphyrin
US4782049A (en) * 1986-12-08 1988-11-01 The Rockefeller University Tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis

Also Published As

Publication number Publication date
EP0333831A4 (en) 1990-06-26
WO1989002269A1 (en) 1989-03-23
DK225689D0 (da) 1989-05-08
DE3872871D1 (de) 1992-08-20
GR880100589A (en) 1989-06-22
AU2525488A (en) 1989-04-17
DE3872871T2 (de) 1992-12-03
ES2012547A6 (es) 1990-04-01
EP0333831A1 (en) 1989-09-27
AU603938B2 (en) 1990-11-29
EP0333831B1 (en) 1992-07-15
GR1000117B (el) 1991-06-28
DK225689A (da) 1989-05-08
JPH02501740A (ja) 1990-06-14
ATE78164T1 (de) 1992-08-15

Similar Documents

Publication Publication Date Title
SE8504945D0 (sv) Pharmaceutical compositions containing anthracycline glycosides
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
ES2074698T3 (es) Composicion oral para el tratamiento de enfermedades intestinales inflamatorias.
GR862316B (en) Emulsion compositions for administation of sparingly water soluble ionizable hydrophobic drugs
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
DK0393575T3 (da) Præparater til behandling af neoplasia indeholdende antineoplastisk middel og beskyttelsesmiddel til formindskelse af bivirkninger
KR960704543A (ko) 악성 질환의 치료를 위한 비경구투여용 부설판(Parenteral Busulfan for treatment of malignant disease)
Dunn et al. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
NO1998012I1 (no) Amfotericin B Lipid-kompleks
SE8602743D0 (sv) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
KR890701108A (ko) 종양요법의 독성효과를 반전시키기 위한 메탈로포르피린의 사용
WO2005025501A3 (en) Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
Le Normand et al. Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients
ES343957A1 (es) Procedimiento de obtencion de polisacaridos sulfatados an- tilipemicos activos por via oral.
EA200100214A1 (ru) Применение производных камптотецина с пониженной гастроинтестинальной токсичностью
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
BE1000540A5 (fr) Solutions injectables pretes a l'emploi contenant un agent antitumeur du type anthracycline-glucoside.
Maeda et al. Antitumor activity of some bacterial proteases: eradication of solid tumors in mice by intratumor injection
KR910004186A (ko) 제약학적 배합물
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
Gahn et al. Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemia
ES2103422T3 (es) Uso de bilobalida y sus derivados para tratar una infeccion en un individuo y composiciones farmaceuticas destinadas a dicho uso.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid